An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb International Corporation0 个研究点目标入组 320 人开始时间: 2012年8月7日最近更新: 2012年12月3日

适应症

试验速览

暂无简介。

•1) men & women ? 18 years of age
•2) Subjects with histologically or cytologically-documented squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection.
•3) Disease recurrence or progression during/after one prior platinum-containing chemotherapy regimen for advanced or metastatic disease
•4) Measurable disease by CT/MRI per RECIST 1.1 criteria
•5) ECOG performance status ? 1
•6) An FFPE tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 160
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

•1) Subjects with active CNS metastases are excluded. Subjects are eligible if CNS metastases are adequately treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ?10mg daily prednisone (or equivalent)
•2) Subjects with carcinomatous meningitis.
•3) Subjects with active, known or suspected autoimmune disease, or subjects with interstitial lung disease.
•4) Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization.
•4) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
•5) Prior treatment on the first line study CA184104 first line NSCLC study
•6) Prior treatment with docetaxel
•7) Treatment with any investigational agent within 28 days of first administration of study treatment.

发起方